相关实验视频

Updated: Jul 23, 2025

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

在神经内分泌瘤中使用lanreotide的现实世界

Zeba Siddiqui¹, Horia Marginean^2,3, Macyn Leung³

¹Internal Medicine Residency Program, The Ottawa Hospital (TOH), Ottawa, ON, Canada.

Journal of gastrointestinal oncology

|July 12, 2023

概括

在加拿大对转移性神经内分泌瘤 (NETs) 的lanreotide的现实世界使用表明它是.

科学领域:

在瘤学瘤学.
内分泌学在内分泌学.

背景情况:

转移性神经内分泌瘤 (NETs) 的治疗通常涉及索马托斯塔丁类似物 (SSAs).
加拿大对兰胺使用的现实数据有限.

研究的目的:

评估在转移性NET患者中兰胺的实际使用情况.
在加拿大中心分析治疗模式,剂量和结果.

主要方法:

对69名NET患者的回顾性图表审查.
作为一线全身治疗的兰类药物的分析,包括剂量和治疗时间.

主要成果:

兰胺是60名患者的第一线治疗,主要用于低度NET.
标准剂量为每28天120毫克是常见的;剂量升级发生在7名患者中.
治疗的平均持续时间为21.6个月,主要目标是控制瘤.

结论:

这些发现与目前在NET中使用SSA的临床指导方针一致.
未来的研究应该探索不断发展的临床实践和剂量升级在疾病控制中的作用.

关键词:

兰雷胺是什么意思神经内分泌神经内分泌在现实世界中使用.索马托斯塔丁类型的类似物.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents

Published on: March 7, 2011

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...